Onkure Therapeutics Inc (OKUR)

Currency in USD
3.560
+0.020(+0.56%)
Closed·
3.5600.000(0.00%)
·
OKUR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.5203.620
52 wk Range
2.2305.380
Key Statistics
Prev. Close
3.54
Open
3.56
Day's Range
3.52-3.62
52 wk Range
2.23-5.38
Volume
131.72K
Average Volume (3m)
282.85K
1-Year Change
25.7951%
Book Value / Share
4.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OKUR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.500
Upside
+335.39%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Onkure Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.500
(+335.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Oppenheimer
Buy14.00+293.26%30.00MaintainAug 14, 2026
H.C. Wainwright
Buy21.00+489.89%27.00MaintainJul 21, 2026
Oppenheimer
Buy30.00+742.70%-New CoverageJun 23, 2026
Jones Trading
Hold---DowngradeMay 06, 2026
Jones Trading
Buy17.00+377.53%-New CoverageApr 06, 2026

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
-0.31 / -0.67
Revenue / Forecast
-- / 166.67K
EPS Revisions
Last 90 days

OKUR Income Statement

Compare OKUR to Peers and Sector

Metrics to compare
OKUR
Peers
Sector
Relationship
P/E Ratio
−2.5x−2.4x−0.4x
PEG Ratio
−0.04−0.030.00
Price/Book
0.8x4.2x2.6x
Price / LTM Sales
-12.2x3.1x
Upside (Analyst Target)
323.7%120.5%49.0%
Fair Value Upside
Unlock−0.5%7.1%Unlock

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.98M7.36%10.55M
Other Institutional Investors
50.70M92.64%179.49M
Public Companies & Retail Investors
0.000.00%0.00
Total
53.68M100.00%190.04M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.9.87%3,998,33314,154
RA Capital Healthcare Fund, L.P.9.87%3,998,33214,154

People Also Watch

22.59
KIDS
-0.92%
115.05
ECG
+2.08%
6.96
STTK
+0.72%

FAQ

What Is the Onkure Therapeutics (OKUR) Stock Price Today?

The Onkure Therapeutics stock price today is 3.560 USD.

What Stock Exchange Does Onkure Therapeutics Trade On?

Onkure Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Onkure Therapeutics?

The stock symbol for Onkure Therapeutics is "OKUR."

What Is the Onkure Therapeutics Market Cap?

As of today, Onkure Therapeutics market cap is 143.360M USD.

What Is Onkure Therapeutics's Earnings Per Share (TTM)?

The Onkure Therapeutics EPS (TTM) is -2.584.

When Is the Next Onkure Therapeutics Earnings Date?

Onkure Therapeutics will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is OKUR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Onkure Therapeutics Stock Split?

Onkure Therapeutics has split 0 times.

How Many Employees Does Onkure Therapeutics Have?

Onkure Therapeutics has 45 employees.

What is the current trading status of Onkure Therapeutics (OKUR)?

As of Sep 03, 2026, Onkure Therapeutics (OKUR) is trading at a price of 3.560 USD, with a previous close of 3.540 USD. The stock has fluctuated within a day range of 3.520 USD to 3.620 USD, while its 52-week range spans from 2.230 USD to 5.380 USD.

What Is Onkure Therapeutics (OKUR) Price Target According to Analysts?

The average 12-month price target for Onkure Therapeutics is 15.500 USD, with a high estimate of 21 USD and a low estimate of 11 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +335.39% Upside potential.

What Is the OKUR Premarket Price?

OKUR's last pre-market stock price is 3.550 USD. The pre-market share volume is 40.000, and the stock has decreased by 0.010, or 0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.